Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
PROVID-CAPNETZ
1 other identifier
observational
400
1 country
15
Brief Summary
The pandemic triggered by the new SARS-CoV-2 presents the German health system with previously unknown challenges. There are currently no effective therapies for the treatment of the SARS-CoV-2 lung disease Covid-19. The aim of the joint project PROVID is to draw conclusions from the often very different clinical appearance of infections with the SARS-CoV-2 pathogen in order to improve patient care through targeted clinical management. The effects of infections with the SARS-CoV-2 pathogen are wide-ranging and include a spectrum from symptomlessness to infections of the upper respiratory tract, uncomplicated but also severe pneumonia with lung failure and high mortality. PROVID will first check whether certain host factors determine the severity and / or the course of Covid-19. Research is also being carried out into whether the molecular and clinical values of Covid-19 patients differ from those of patients with pneumonia caused by other pathogens. In addition, it will be tested whether specific molecular markers describe the severity of the disease and are suitable as an aid for targeted therapy for Covid-19. PROVID is an interdisciplinary joint project made up of three sub-projects that are being implemented at three locations (Charitè-Universitätsmedizin Berlin, Universität Leipzig IMISE and CAPNETZ STIFTUNG / Hannover). PROVID is based on three clinical research platforms with a high track record in recruiting patients with high-quality data and biomaterials on the one hand and guideline-changing results on the other hand: CAPNETZ (competence network CAP, since 2002, world's largest database and biobank for CAP), PROGRESS (Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis, since 2007) and CAPSyS (systems medicine of community-acquired pneumonia, since 2014). The COVID-19 patients are recruited into 3 different patient cohorts via these 3 research platforms. 1\. PROVID-CAPNETZ, 2. PROVID-PROGRESS, 3. PROVID-CAPSyS.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2020
15 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2020
CompletedFirst Submitted
Initial submission to the registry
October 27, 2020
CompletedFirst Posted
Study publicly available on registry
July 7, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2022
CompletedJuly 7, 2021
October 1, 2020
1.3 years
October 27, 2020
July 2, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Determination of the host- and virusdependent mechanisms associated with the clinical appearence of COVID-19
Determination of specific molecular markers
up to 1 year
Determination of the course of COVID-19
Host factors (transcriptional response/RNA, proteins, antibodies) determine the course of COVID-19
up to 1 year
Determination of the severity of COVID-19
Host factors (transcriptional response/RNA, proteins, antibodies) determine the severity of COVID-19
up to 1 year
Eligibility Criteria
Patients with positive detection of the SARS-CoV-2 virus (Coronavirus disease-19 (COVID-19))
You may qualify if:
- Age ≥ 18
- Radiological proof of infiltrate (primarily chest x-ray or CT) with positive detection of SARS-CoV-2-virus or with no proven infiltrate with positive detection of SARS-CoV-2-virus
- Informed consent signed
You may not qualify if:
- Newly diagnosed, active pulmonary tuberculosis within the last 2 months
- Simultaneous participation in PROVID-PROGRESS or PROVID-CAPSyS cohort
- Participation of the patient in PROVID-PROGRESS or PROVID-CAPSyS cohort at an earlier point in time
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hannover Medical Schoollead
- Charite University, Berlin, Germanycollaborator
- University of Leipzigcollaborator
Study Sites (15)
Krankenhaus Bad Arolsen
Bad Arolsen, Germany
Charité - Universitätsmedizin Berlin
Berlin, Germany
HELIOS Klinikum Emil von Behring Berlin
Berlin, Germany
Vivantes Klinikum Neukölln
Berlin, Germany
Krankenhaus der Augustinerinnen
Cologne, Germany
Carl-Thiem-Klinikum Cottbus
Cottbus, Germany
Klinikum Dortmund gGmbH
Dortmund, Germany
Universitätsklinikum Dresden
Dresden, Germany
Universitätsklinikum Frankfurt
Frankfurt, Germany
Klinik Schillerhöhe
Gerlingen, Germany
Hannover Medical School
Hanover, Germany
Universitätsklinikum Jena
Jena, Germany
Universitätsklinikum Schleswig-Holstein Campus Lübeck
Lübeck, Germany
Universitätsklinikum rechts der Isar
München, Germany
Agaplesion Diakonieklinikum Rotenburg
Rotenburg (Wümme), Germany
Related Links
Biospecimen
Blood, urine and materials of the respiratory tracts (upper and lower respiratory tracts)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Grit Barten-Neiner
CAPNETZ Stiftung
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 27, 2020
First Posted
July 7, 2021
Study Start
October 1, 2020
Primary Completion
January 1, 2022
Study Completion
July 1, 2022
Last Updated
July 7, 2021
Record last verified: 2020-10